[DealSite Reporter Da-eun Lee] Mezoo is pursuing expansion into a healthcare platform company based on its ambulatory Remote Patient Monitoring (aRPM) technology. Starting from an on-device AI–based patch-type medical device, the company plans to broaden its business scope to include the semiconductor-based ‘µBIC chip,’ which implements a biosignal processor, as well as the consumer platform ‘HiCardi Wellness.’
Mezoo’s flagship product is the wearable remote patient monitoring platform ‘HiCardi.’ The device is designed to measure key biosignals such as ECG, respiration, body temperature, and activity levels with a single patch, delivering the data to medical professionals through a mobile application and cloud system.
The technological foundation lies in its proprietary biosignal processor. Mezoo has implemented a range of biosignal analysis algorithms in chipset form, enabling real-time data processing even in wearable devices. With this approach, a wearable medical device can be realized by integrating only a compact chip.
In particular, unlike most wearable medical devices that rely on cloud-based computation, Mezoo applies ‘on-device AI’ technology that processes data directly within the device. This allows the system to achieve both low-power operation and fast data processing, enabling continuous monitoring for up to 72 hours.
